Comparison · NCT01880593-0d5fcd5d
Ketamine and Lithium vs Ketamine and Placebo: Patient Rated Inventory of Side Effects (PRISE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ketamine and Lithium vs Ketamine and Placebo: Patient Rated Inventory of Side Effects (PRISE). Trial comparisons, record NCT01880593-0d5fcd5d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01880593-0d5fcd5d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0584 | 0.392 | wilson | |
| Risk in group 2 | 0.125 | 0.035 | 0.36 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0417 | -0.217 | 0.285 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.254 | 7 | log | |
| Odds ratio, group 1 over group 2 | 1.4 | 0.203 | 9.66 | log | |
| Number needed to treat, for one more participant with the outcome on Ketamine and Lithium than on Ketamine and Placebo | 24 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ketamine and Lithium | 600-1200mg of Lithium pills at night for duration of the study | 3 | 18 | OG000 |
| Group 2 | Ketamine and Placebo | Placebo pills at night for duration of the study | 2 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Patient Rated Inventory of Side Effects (PRISE)
- Description
- Number of Participants with PRISE
- Time frame
- 2 weeks after last ketamine infusion
- Population
Source ClinicalTrials.gov
Trial
- Title
- Ketamine Plus Lithium in Treatment-Resistant Depression
- NCT number
- NCT01880593
- Phases
- PHASE2
- Conditions
- Depression
- Interventions
- Lithium, Ketamine, Placebo
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Results first posted
- 2018-07-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01880593?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01880593-0d5fcd5d